About Biomedicines

Aims

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, clinical studies and applications, biomaterial in biomedical research, natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology-driven products, targeted therapy, bioimaging, biosensors, biomarkers, biosimilars, and nano-biosimilars.

We encourage authors to publish their experimental, theoretical, and computational results in as much detail as possible. There is no restriction on the maximum length of papers or the number of electronic multimedia and supplementary files. For all articles, the full experimental details must be provided so that the results can be reproduced. Electronic files regarding the full details of the experimental procedure, if unable to be published in a normal way, can be deposited as Supplementary Materials (including animated pictures, videos, interactive Excel sheets, software executables and others).

Scope

Biomedicines publishes high-quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, development, and, ultimately, to clinical use. Therefore, laboratory medicine research, translation medical research, comprehensive preclinical studies, and most clinical studies focused on development and early phase clinical trials are all within the scope of the journal. Some topics include the following:

• Pathogenesis and mechanisms of diseases;
• Cardiovascular diseases;
• Biomaterial in biomedical research;
• Novel targets in various therapeutic areas: cardiovascular, vascular, hematology, oncology, neurology, orthopedics, dermatology, ophthalmology;
• Biomarker discovery and early diagnosis research;
• Drug discovery and development, pharmacotherapy;
• Basic and clinical pharmacology;
• Biopharmaceutical biomedicine: biologics and biosimilars;
• Nanobiotechnological advances in biomedicine: nanomedicine, nanoscaffold implants (synthetic vascular graft), biosensors, bioimaging, gene therapy, vaccine, cell therapy, and tissue engineering;
• Neurobiology and clinical neuroscience;
• Neuromodulation.

MDPI Publication Ethics Statement

MDPI is a member of the Committee on Publication Ethics (COPE). MDPI takes the responsibility to enforce a rigorous peer-review together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, inappropriate authorship credit, and the like, do arise. MDPI takes such publishing ethics issues very seriously and our editors are trained to proceed in such cases with a zero tolerance policy. To verify the originality of content submitted to our journals, we use iThenticate to check submissions against previous publications.

Book Reviews

Authors and publishers are encouraged to send review copies of their recent related books to the following address. Received books will be listed as Books Received within the journal's News & Announcements section.

MDPI
St. Alban-Anlage 66
CH-4052 Basel
Switzerland

Copyright / Open Access

Articles published in Biomedicines will be Open-Access articles distributed under the terms and conditions of the Creative Commons Attribution License (CC BY). The copyright is retained by the author(s). MDPI will insert the following note at the end of the published text:

Reprints

Reprints may be ordered. Please contact for more information on how to order reprints.

Announcement and Advertisement

Announcements regarding academic activities such as conferences are published for free in the News & Announcements section of the journal. Advertisement can be either published or placed on the pertinent website. Contact e-mail address is .

Editorial Office

For further MDPI contacts, see here.